Spencer Feldman

EHA 2026 brought new data on myeloma, leukemia and lymphoma. Here's what patients and caregivers should know about five key studies.

Tammy Zinn, a finalist for the Extraordinary Healer Award, reflects on the personal loss that led her to oncology nursing and the programs she built to support patients.

In a Q&A with CURE, oncology nurse Jill Winther reflects on advocacy, holistic care, and what's kept her in the field for 35 years.

Oncology nurse Tammy Zinn, an Extraordinary Healer finalist, discusses hope, advocacy, and launching Emma's Wish for patients with cancer.

Oncology nurse Jill Winther discusses why understanding treatment reasoning and advocating for patients matters most in cancer care.

10 Things That Got Me Through Treatment ft. Kiana Wooten

After surviving breast cancer and relapsed non-Hodgkin lymphoma, Maitte Penalver is helping Hispanic patients with cancer feel seen, heard and supported through advocacy and education.

Survivorship coach Eileen Lopez Tomei discusses the unique cultural barriers Hispanic and Latina cancer survivors face and why bilingual community events matter.

After a stage 4 colon cancer diagnosis at age 40, survivor Kasia Orzechowska now advocates for early screening and self-advocacy to help save lives.

Psychologist Ian Sadler explains why many patients with cancer face anxiety and emotional challenges after treatment ends and why mental health support matters.

Mariska Hargitay discusses her father's myeloma, hope from research and the importance of community and caregivers for patients.

MosunPola improved progression-free survival and response rates over R-GemOx in transplant-ineligible relapsed large B-cell lymphoma.

Appeals, peer-to-peer reviews and external reviews often overturn insurance denials, helping patients access recommended cancer care.

Investigational bispecific antibody pumitamig achieved a 70% response rate and disease control in all evaluable patients with advanced NSCLC.

ASCO 2026 highlighted advances in pancreatic, breast, sarcoma, lung and prostate cancers that may reshape treatment.

FDA approved Cavhanza, a new nilotinib formulation for adults with Ph+ CML that may offer more flexible dosing and easier administration.

Iza-bren improved survival and delayed disease progression versus chemotherapy in previously treated metastatic triple-negative breast cancer.

Giredestrant plus Afinitor improved disease control after later treatment and delayed chemotherapy in ER-positive, HER2-negative breast cancer.

Sac-TMT plus Keytruda helped patients with PD-L1–positive advanced NSCLC live longer without their cancer worsening and increased response rates versus Keytruda alone.

A cancer survivor’s wife created a life transition binder during his treatment to organize medical, financial and household information to access details in emergencies.

FDA approves Decnupaz for adults with BPDCN, with 69.7% of treatment-naïve patients achieving remission in the CADENZA trial.

FDA approved Datroway for unresectable or metastatic triple-negative breast cancer not eligible for PD-1 or PD-L1 therapy with PFS, OS and response rates vs chemotherapy.

ASCO 2026 will highlight biomarker-driven lung cancer care, targeted therapies, ADCs and phase 3 trials shaping precision oncology advances.

The FDA approved Enhertu for certain patients with HER2-positive early-stage breast cancer before and after surgery based on DESTINY trial data.

Jill Winther earned CURE’s 2026 Extraordinary Healer® Award for her leadership, advocacy and dedication to oncology nursing.

Oncology dietitians shared smoothie and turmeric latte recipes to help patients with breast cancer manage nutrition during treatment.

Edward Miskie shares how survivorship can feel isolating, inspiring the Remission Film Festival to spotlight the emotional realities after treatment.

New therapies are beginning to crack KRAS, offering tumor shrinkage and longer survival as researchers work to overcome resistance.

New immunotherapy use before and after surgery improves outcomes, making early symptom recognition and expert care more critical than ever.

New T-cell engagers and ADCs show survival gains in pretreated small cell lung cancer, signaling long-awaited progress and more treatment options for patients.